Palleon Pharmaceuticals

📍 Waltham, United States🗓 Founded 2016👥 44 employees💰 Last funded Oct 2020
Biotechnology Research🌐 palleonpharma.com
Website LinkedIn
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis. The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2016
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Palleon Pharmaceuticals?
Palleon Pharmaceuticals has 2 investors on record on gritt.io, 2 mid-stage.
When did Palleon Pharmaceuticals last raise funding?
The most recent investment in Palleon Pharmaceuticals recorded on gritt.io was in October 2020.
When was Palleon Pharmaceuticals founded?
Palleon Pharmaceuticals was founded in 2016.
What industry is Palleon Pharmaceuticals in?
Palleon Pharmaceuticals operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Palleon Pharmaceuticals based?
Palleon Pharmaceuticals is headquartered in Waltham, United States.